1298 related articles for article (PubMed ID: 21974995)
1. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
2. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
[TBL] [Abstract][Full Text] [Related]
6. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
[TBL] [Abstract][Full Text] [Related]
7. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
[TBL] [Abstract][Full Text] [Related]
8. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.
Faenzi E; Zedda L; Bardelli M; Spensieri F; Borgogni E; Volpini G; Buricchi F; Pasini FL; Capecchi PL; Montanaro F; Belli R; Lattanzi M; Piccirella S; Montomoli E; Ahmed SS; Rappuoli R; Del Giudice G; Finco O; Castellino F; Galli G
Vaccine; 2012 Jun; 30(27):4086-94. PubMed ID: 22521851
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
10. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
11. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ
Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
13. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
14. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.
Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E
J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
16. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
Tremblay CL; Rouleau D; Fortin C; Toma E; Sylla M; Cyr L; Cote S; Baz M; Sampalis J; Trautman L; Sékaly RP; Boivin G
Vaccine; 2011 Feb; 29(7):1359-63. PubMed ID: 21185423
[TBL] [Abstract][Full Text] [Related]
18. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
20. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
Kajaste-Rudnitski A; Galli L; Nozza S; Tambussi G; Di Pietro A; Pellicciotta G; Monti A; Mascagni P; Moro M; Vicenzi E
AIDS; 2011 Jan; 25(2):177-83. PubMed ID: 21150561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
